Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

A Phase 1 study of the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium), a novel Class E capsid assembly modulator, in healthy participants

Friday, November 21, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: A Phase 1 study is being conducted to evaluate the safety, tolerability, and pharmacokinetics of ALG-000184 (pevifoscorvir sodium) in healthy participants. This novel Class E capsid assembly modulator targets chronic HBV infection. The trial's results could provide insights into the drug's potential effectiveness and safety profile.
Price reaction · baseline $8.26 (2025-11-20 close) · hit pre-market · clean, no other ALGS news in the window
day 0 close
+11.5%
day 1
+15.2%
day 3 · peak
+19.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • The study focuses on a novel treatment for chronic HBV infection.
  • It aims to assess safety and tolerability in healthy participants.
  • The drug, ALG-000184, represents a new class of capsid assembly modulators.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184, also known as pevifoscorvir sodium, is a novel Class E capsid assembly modulator.

What does the Phase 1 study evaluate?

The Phase 1 study evaluates the safety, tolerability, and pharmacokinetics of ALG-000184.

Who are the participants in the study?

The study involves healthy participants to assess the drug's safety profile.

What condition does ALG-000184 target?

ALG-000184 targets chronic HBV infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 pevifoscorvir sodium chronic HBV infection capsid assembly modulator clinical trials
Last updated: Nov 21, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →